|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/02 | (2006.01) |
| (11) | Number of the document | 3556775 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19161885.9 |
| Date of filing the European patent application | 2015-01-26 | |
| (97) | Date of publication of the European application | 2019-10-23 |
| (45) | Date of publication and mention of the grant of the patent | 2021-11-17 |
| (46) | Date of publication of the claims translation | 2022-01-25 |
| (30) | Number | Date | Country code |
| 201461932589 P | 2014-01-28 | US |
| (72) |
GUTIERREZ, Andres A. , US
GROSSO, Joseph , US
HILL, Christopher Mark , US
SELBY, Mark , US
LEWIS, Katherine E. , US
|
| (73) |
Bristol-Myers Squibb Company ,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Anti-LAG-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui |
| ANTI-LAG-3 ANTIBODIES TO TREAT HEMATOLOGICAL MALIGNANCIES |
| Payment date | Validity (years) | Amount | |
| 2024-12-19 | 11 | 289.00 EUR |
| 2026-01-26 |